Bradley Rupp, MD
Urology · Topeka, KSNPI 1710953518
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.2% of the total across 184 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $840 and has fallen 54.3% since, to $384 in 2025.
Across 184 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$651
- AbbVie$341
- Myriad Genetic Laboratories, Inc.$192
- Urovant Sciences Inc$181
- Teleflex LLC$173
- Sumitomo Pharma America, Inc.$171
- plus $2K from 31 others
What the payments were for
- Food & beverage$2,95991%
- Education$2869%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 32 | $651 |
| AbbVie | 23 | $341 |
| Myriad Genetic Laboratories, Inc. | 10 | $192 |
| Urovant Sciences Inc | 18 | $181 |
| Teleflex LLC | 8 | $173 |
| Sumitomo Pharma America, Inc. | 11 | $171 |
| Pfizer | 11 | $165 |
| Urogen Pharma, Inc. | 5 | $119 |
| Tolmar Pharmaceuticals, Inc. | 6 | $115 |
| Merck | 5 | $114 |
| Kowa Pharmaceuticals America, Inc. | 7 | $101 |
| Johnson & Johnson | 4 | $93 |
| Endo Pharmaceuticals Inc. | 5 | $92 |
| Dendreon Pharmaceuticals LLC | 4 | $70 |
| Immunitybio, Inc. | 3 | $66 |
| Procept Biorobotics Corporation | 3 | $54 |
| Caldera Medical, Inc | 1 | $46 |
| Myovant Sciences Inc. | 3 | $43 |
| Olympus America Inc. | 2 | $40 |
| Accord Healthcare, Inc. | 2 | $40 |
| Kerecis Limited | 2 | $40 |
| Antares Pharma, Inc. | 2 | $39 |
| Convatec Inc. | 2 | $35 |
| Davol Inc. | 1 | $33 |
| Blue Earth Diagnostics | 2 | $27 |
| Laborie Medical Technologies Corp. | 1 | $23 |
| Novartis | 1 | $23 |
| Ambu Inc. | 1 | $21 |
| Neotract Inc. | 1 | $21 |
| Sanofi | 1 | $18 |
| Rochester Medical Corporation | 1 | $18 |
| Progenics Pharmaceuticals, Inc. | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
| KARL Storz Endoscopy-america | 1 | $14 |
| Medtronic | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
| Bard Access Systems, Inc. | 1 | $11 |
How this compares
$3,245 in reported general payments places this provider in the 55th percentile of 111 urology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 71 | $41,054 |
| GemtesaVibegron | 57 | $38,640 |
| Tamsulosin Hcl | 1,285 | $12,407 |
| Finasteride | 483 | $5,900 |
| Oxybutynin Chloride ErOxybutynin Chloride | 180 | $5,763 |
| Silodosin | 41 | $2,604 |
| Bicalutamide | 49 | $1,898 |
| Potassium Citrate ErPotassium Citrate | 28 | $1,625 |
| Testosterone | 21 | $1,573 |
| Solifenacin Succinate | 58 | $1,381 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 73 | $1,241 |
| Dutasteride | 44 | $1,079 |
| Cefdinir | 53 | $856 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 49 | $759 |
| Terazosin Hcl | 41 | $632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $651 | $41,05471 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $171 | $38,64057 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 111 urology providers in Kansas.
Other urology in Topeka
- Loren SmithTopeka$4K
- Timothy RichardsonWichita$493K
- Wilson MolinaKansas City$239K
- Bristol WhilesKansas City$163K
- Jeffrey HolzbeierleinKansas City$78K
- Ahmad El-ArabiKansas City$55K
- David DucheneKansas City$33K
- Jason AnastOverland Park$31K
- Son NguyenMerriam$27K
- Joshua BroghammerKansas City$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.